For the full year 2026, PTC anticipates: Total product revenue of $700M-$800M, excluding Evrysdi royalty revenue and collaboration revenue; GAAP R&D and SG&A expense of $775M-$815M; Non-GAAP R&D and SG&A expense of $680M-$720M, excluding estimated non-cash, stock-based compensation expense of $95M.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics price target raised to $90 from $78 at Morgan Stanley
- PTC Therapeutics Fully Monetizes Evrysdi Royalty Interest
- PTC Therapeutics announces Japanese MHLW approval of Sephience
- PTC Therapeutics: Strong Growth Potential Driven by R&D Expertise and Successful Sephience Launch
- Carvana initiated, Zscaler downgraded: Wall Street’s top analyst calls